Aegon Ltd. vs TransMedics Group Inc — how do they compare? Aegon Ltd. trades at $9.42 (market cap $14.01B), while TransMedics Group Inc trades at $87.13 (market cap $3.10B). The key difference: Aegon Ltd. is far larger — about 4.5× TransMedics Group Inc's market cap, and Aegon Ltd. pays a 4.94% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| AEG | TMDX | |
|---|---|---|
Market Cap | $14.01B | $3.10B |
Sector | Financials | Technology |
52-Week High | $9.53 | $150.42 |
52-Week Low | $6.79 | $61.99 |
Enterprise Value | $15.16B | $3.49B |
Dividend Yield | 4.94% | — |
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.41, down 0.48% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $19.5B in 2024 to $26.9B in 2025 and net income increasing to $977M. Recent strategic moves include relocating to Delaware and simplifying governance while maintaining a dividend payout. Analyst consensus is mixed with 28% buy ratings but 50% hold recommendations.
AEG presents a turnaround story with improving profitability and strategic refocusing on US markets. Key opportunities include continued earnings growth and potential buybacks, while risks involve execution of the US transition and maintaining momentum amid volatile cash flow patterns. The stock offers value with a P/E of 13.5 and P/S of 0.57.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Trailing returns across standard periods
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →